The first PD-L1 inhibitor for the treatment of gastric cancer, Pfizer Zeteme, has been approved for its fifth indication
123458015
发表于 2024-3-15 14:32:22
1260
0
0
On March 15th, Pfizer announced that its innovative tumor immunotherapy drug, Serenigme (Shuglizumab Injection), has been approved by the National Medical Products Administration for first-line treatment of locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (G/GEJ) expressing PD-L1, in combination with fluorouracil and platinum containing drugs, Becoming the world's first PD-L1 monoclonal antibody approved for indication in gastric/gastroesophageal junction adenocarcinoma.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
